Gary J. Nabel, Ph.D. is Senior Vice President, Chief Scientific Officer and Deputy to the President for Global R&D at Sanofi. Gary also serves as Chairman of the Strategic Development and Scientific Advisory Council (SDSAC).
Dr. Gary Nabel joined Sanofi in November 2012 from the National Institutes of Health, where he served as Director of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases since 1999. During his tenure at the NIH, Dr. Nabel provided overall direction and scientific leadership of the basic, clinical and translational research activities of the VRC and guided development of novel vaccine strategies against HIV and other emerging and re-emerging infectious diseases, including Ebola/Marburg hemorrhagic fevers, influenza, chikungunya and other viruses.
Dr. Nabel graduated magna cum laude from Harvard College in 1975 and continued his graduate studies at Harvard, completing his Ph.D. in 1980 and his M.D. two years later. He then served as a postdoctoral fellow in the laboratory of David Baltimore at MIT's Whitehead Institute. Before his appointment at the VRC, Dr. Nabel served as the Henry Sewall Professor of Internal Medicine, Professor of Biochemistry, and Howard Hughes Medical Institute Investigator at the University of Michigan in Ann Arbor. In addition to his faculty positions, Dr. Nabel also served as the Director of the Center for Gene Therapy and Co-Director of the Center for Molecular Medicine at the University of Michigan.
In recognition of his expertise at the forefront of virology, immunology, gene therapy and molecular biology, Dr. Nabel was elected to the Institute of Medicine of the National Academy of Sciences in 1998. Among his many honors, Dr. Nabel received the Amgen Scientific Achievement Award from the American Society for Biochemistry and Molecular Biology and the Health and Human Services Secretary's Award for Distinguished Service. He is a fellow of the American Association of Physicians and the American Academy of Arts and Sciences.